TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

NASDAQ
$143.82
▼ $86.89 (-37.7%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $380.00L $143.40-49.9%
$380$332.68$285.36$238.04$190.72$143.4$143.82
RSI (14)
Intraday · 15-minSell-30RSI 21DowntrendMACD Bearishfor day-trading context — not advice

Technical signal

Sell-15
RSI (14)26
oversold 30overbought 70
Trend
Downtrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$143.40
Resistance
$232.88
  • Price is below its 50-day average (medium-term weakness).
  • RSI is 26 — oversold, a level some traders read as a potential entry zone.

Signal backtest · 2026-02-20 → 2026-11-20

Strategy return
-25.3%
Buy & hold
-57.2%
Trades
7
Win rate
0%

$100,000.00 invested would be worth $74,727.35 (-25.3%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Alnylam Pharmaceuticals, Inc.· Biotechnology

source: yahoo

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Employees
2,500
Headquarters

Fundamentals

source: yahoo
Market cap
$19.26B
P/E
7.3
P/B
5.3
EPS
$19.80
Div yield
0.0%
Profit margin
52.8%
ROE
138.1%
Debt / Equity
0.83
Beta
0.44
52-week range
$143.40 – $479.79
52-week low · $143.400% of rangehigh · $479.79

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:— Neutral2↑ · 2↓ · 4–
  • Alnylam Pharmaceuticals Expands Sales Force to Accelerate AMVUTTRA Demand▲ Positive
    MarketBeat · 20 Nov 2026
  • Alnylam to Webcast Presentations at Upcoming December Investor Conferences— Neutral
    Business Wire · 20 Nov 2026
  • Alnylam (ALNY) Stock Looks Undervalued As Shares Fell 68%▼ Negative
    Simply Wall St. · 19 Nov 2026
  • Alnylam Pharmaceuticals (ALNY) Stock Dropped, So What Is Driving Attention Now?

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Cambridge, United States
www.alnylam.com ↗
— Neutral
Simply Wall St. · 19 Nov 2026
  • Analysts Turned Bearish on These 5 Stocks on Wednesday▼ Negative
    Insider Monkey · 19 Nov 2026
  • With FDA nod, Regeneron brings an RNAi drug to autoimmune disease— Neutral
    BioPharma Dive · 19 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.